Enrollment in Phase 2 Study of Cognitive Treatment Paused for Pandemic

Enrollment in Phase 2 Study of Cognitive Treatment Paused for Pandemic
Aptinyx has paused patient enrollment in its Phase 2 trial evaluating NYX-458 to treat mild cognitive impairment in people with Parkinson’s disease due to the current COVID-19 pandemic The decision was made in light of the elevated risk this virus poses to an older patient population, and the challenges in assessing changes in cognitive skills remotely.  “In the midst of the ... read more
Source: Parkinson’s News TodayPublished on 2020-05-19By Vanessa Pataia